During the past decade, Zhejiang Cancer Hospital conducted 400 clinical trials. In the 10-year time frame, 400 clinical trials started and 51 clinical trials were completed, i.e. on average, 12.8% percent of trials that started reached the finish line to date. In the past 5 years, 250 clinical trials started and 43 clinical trials were completed. i.e. 17.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Zhejiang Cancer Hospital" #1 sponsor was "Zhejiang Cancer Hospital" with 114 trials, followed by "Hoffmann-La Roche" with 43 trials sponsored, "BeiGene" with 34 trials sponsored, "Merck Sharp & Dohme LLC" with 16 trials sponsored and "Jiangsu HengRui Medicine Co., Ltd." with 16 trials sponsored. Other sponsors include 242 different institutions and companies that sponsored additional 126 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Zhejiang Cancer Hospital" #1 collaborator was "Zhejiang Cancer Hospital" with 16 trials as a collaborator, "Fudan University" with 11 trials as a collaborator, "Eisai Inc." with 8 trials as a collaborator, "Eli Lilly and Company" with 7 trials as a collaborator and "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 6 trials as a collaborator. Other collaborators include 274 different institutions and companies that were collaborators in the rest 201 trials.

According to Clinical.Site data, the most researched conditions in "Zhejiang Cancer Hospital" are "Breast Cancer" (34 trials), "Non-small Cell Lung Cancer" (24 trials), "Gastric Cancer" (18 trials), "Nasopharyngeal Carcinoma" (18 trials) and "Carcinoma, Non-Small-Cell Lung" (16 trials). Many other conditions were trialed in "Zhejiang Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Zhejiang Cancer Hospital" are "Drug" (398 trials), "Radiation" (41 trials), "Biological" (38 trials), "Other" (26 trials) and "Procedure" (20 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (52 trials), "Cisplatin" (31 trials), "Carboplatin" (26 trials), "Tislelizumab" (25 trials) and "Capecitabine" (24 trials). Other intervention names were less common.

The vast majority of trials in "Zhejiang Cancer Hospital" are 402 trials for "All" genders, 59 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are 269 active trials in "Zhejiang Cancer Hospital". 14 are not yet recruiting, 157 are recruiting, 96 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 82 completed trials in Zhejiang Cancer Hospital, 1 suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Zhejiang Cancer Hospital, 62 "Phase 1" clinical trials were conducted, 191 "Phase 2" clinical trials and 193 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 25 trials that are defined as “Not Applicable".

Zhejiang Cancer Hospital has several departments that took part in Clinical trials: "Zhejiang Cancer Hospital; Breast Surgery" - 2 trials